NLR is predictive of upstaging at the time of radical cystectomy for patients with urothelial carcinoma of the bladder

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 5, 2014, Pages 631-636

  Potretzke, Aaron ^a   Hillman, Luke ^b   Wong, Kelvin ^a   Shi, Fangfang ^a   Brower, Ryan ^b   Mai, Stephanie ^b   Cetnar, Jeremy P ^c   Abel, Edwin Jason ^a,c   Downs, Tracy M ^a,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Bladder cancer; Lymphocyte; Neoadjuvant chemotherapy; Neutrophil; Upstaging

Indexed keywords

ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CELLULAR PARAMETERS; CYSTECTOMY; DISEASE SEVERITY; FEMALE; HUMAN; HYDRONEPHROSIS; INSTITUTIONAL REVIEW; LYMPH NODE; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUTROPHIL LYMPHOCYTE RATIO; OUTCOME ASSESSMENT; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SEX DIFFERENCE; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TUMOR INVASION; UNITED STATES; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; BLOOD; CARCINOMA; CYTOLOGY; LYMPHOCYTE; LYMPHOCYTE COUNT; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPHIL; PATHOLOGY; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS; UROTHELIUM;

AGED; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; FEMALE; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEUTROPHILS; PROGNOSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84902545451     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.12.009     Document Type: Article

References (21)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
2. Chang B.S., Kim H.L., Yang X.J., Steinberg G.D. Correlation between biopsy and radical cystectomy in assessing grade and depth of invasion in bladder urothelial carcinoma. Urology 2001, 57:1063-1066. [discussion 6-7].
3. Turker P., Bostrom P.J., Wroclawski M.L., et al. Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. BJU Int 2012, 110:804-811.
4. Shariat S.F., Palapattu G.S., Karakiewicz P.I., et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 2007, 51:137-151.
5. Svatek R.S., Shariat S.F., Novara G., et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int 2011, 107:898-904.
6. Margel D., Harel A., Yossepowitch O., Baniel J. A novel algorithm to improve pathologic stage prediction of clinically organ-confined muscle-invasive bladder cancer. Cancer 2009, 115:1459-1464.
7. McMillan D.C. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr 2009, 12:223-226.
8. Grossman H.B. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. New Engl J Med 2003, 349:859.
9. Karakiewicz P.I., Shariat S.F., Palapattu G.S., et al. Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol 2006, 50:1254-1262.
10. Mitra A.P., Skinner E.C., Miranda G., Daneshmand S. A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer. BJU Int 2013, 111:240-248.
11. Raj G.V., Karavadia S., Schlomer B., et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer 2011, 117:276-282.
12. David K.A., Milowsky M.I., Ritchey J., Carroll P.R., Nanus D.M. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol 2007, 178:451-454.
13. Totaro A., Pinto F., Brescia A., et al. Imaging in bladder cancer: present role and future perspectives. Urol Int 2010, 85:373-380.
14. Cowan N.C., Crew J.P. Imaging bladder cancer. Curr Opin Urol 2010, 20:409-413.
15. Moses K.A., Zhang J., Hricak H., Bochner B.H. Bladder cancer imaging: an update. Curr Opin Urol 2011, 21:393-397.
16. Sr W., Cook E.J., Goulder F., Justin T.A., Keeling N.J. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005, 91:181-184.
17. Wilcox R.A. Cancer-associated myeloproliferation: old association, new therapeutic target. Mayo Clin Proc 2010, 85:656-663.
18. Gondo T., Nakashima J., Ohno Y., et al. Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology 2012, 79:1085-1091.
19. Krane L.S., Richards K.A., Kader A.K., Davis R., Balaji K.C., Hemal A.K. Preoperative neutrophil lymphocyte ratio predicts overall survival and extravesical disease in patients undergoing radical cystectomy. J Endourol 2013, 27:1046-1050.
20. Demirtas A., Sabur V., Akinsal E.C., et al. Can neutrophil-lymphocyte ratio and lymph node density be used as prognostic factors in patients undergoing radical cystectomy?. ScientificWorldJournal 2013, 2013:703579.
21. Chua W., Charles K.A., Baracos V.E., Clarke S.J. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011, 104:1288-1295.